Clinical Trial Update: Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit [Phase 1]

View source ↗

Summary

A completed Phase 1 dose-escalation study of BI 2536 BS in patients with advanced solid tumors evaluated safety, tolerability, and preliminary activity with rep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BI 2536 BS (BI-2536)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED